PFS
TCRR

Prospera Financial Services’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Prospera Financial Services’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed – – 2755
2022
Q1 		$0 Buy
+100
New +$315 ﹤0.01% 2792

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Prospera Financial Services's TCRR Position: Q2 2022 in Review

Prospera Financial Services sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 100 shares.

Prospera Financial Services first reported a position in TCRR in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Prospera Financial Services reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 100 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022.
  • Prospera Financial Services first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's TCR2 Therapeutics Inc. Common Stock position peaked at $0 in Q1 2022.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.